Nakai T, Iwamura Y, Kato K, Hirano I, Matsumoto Y, Tomioka Y, Yamamoto M, Suzuki N*.

Drugs activating hypoxia-inducible factors correct erythropoiesis and hepcidin levels via renal EPO induction in mice.

Blood Adv. 2023 May 5, 7(15):3793-3805: doi: 10.1182/bloodadvances.2023009798. PMID: 37146271. (Featured article)

Shimizu R, Hirano I, Hasegawa A, Suzuki M, Otsuki A, Taguchi K, Katsuoka F, Uruno A, Suzuki N, Yumoto A, Okada R, Shirakawa M, Shiba D, Takahashi S, Suzuki T, Yamamoto M.

Nrf2 alleviates spaceflight-induced immunosuppression and thrombotic microangiopathy in mice.

Commun Biol. 2023 Aug 25;6(1):875. doi: 10.1038/s42003-023-05251-w. PMID: 37626149; PMCID: PMC10457343.

石岡広崇, 鈴木教郎*

腎臓病と低酸素応答機構

腎臓内科 17(6), 714–720, 2023

Iwamura Y, Nakai T, Kato K, Ishioka H, Yamamoto M, Hirano I, Suzuki N.

Hypoxia inducible factor 2 alpha and histone deacetylases control erythroid growth factor in embryonic neural cells with their development.

KEYSTONE SYMPOSIA on Hypoxia. Killarney, Ireland, May 28-31, 2023 (Poster)

Nakai T, Iwamura Y, Kato K, Hirano I, Matsumoto Y, Tomioka Y, Yamamoto M, Suzuki N.

Pharmacological activation of hypoxia-inducible factors promotes erythropoiesis and suppresses hepcidin production by inducing erythropoietin production in the kidneys.

KEYSTONE SYMPOSIA on Hypoxia. Killarney, Ireland, May 28-31, 2023 (Poster)